|
|
 Previous Article | Table of Contents | Next Article 
Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-
risk" disease?
MA Shipp
Department of Medicine, Dana Farber Cancer Institute, Boston, MA.
As the above-mentioned cellular and molecular parameters and newly
identified biologic features are evaluated in larger numbers of patients
with aggressive NHL, the biologic heterogeneity of this disease will be
better appreciated. With a more complete understanding of the disease, it
is likely that we will substitute biologic variables for clinical surrogate
features in our prognostic factor models and target these biologic
variables for therapy in specific subsets of patients. In the meantime,
widely accepted clinical models such as the International Index and the
age-adjusted index will aid in the identification of specific patient risk
groups and the ongoing comparison of different therapeutic approaches.
Early restaging with sensitive techniques like Ga-67 citrate scans may also
identify patients with suboptimal responses to induction therapy at
timepoints when additional therapeutic alternatives may be most effective.
Volume 83,
Issue 5,
pp. 1165-1173,
03/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Dierlamm, E. M. Murga Penas, S. Bentink, S. Wessendorf, H. Berger, M. Hummel, W. Klapper, D. Lenze, A. Rosenwald, E. Haralambieva, et al.
Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma
Haematologica,
May 1, 2008;
93(5):
688 - 696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, et al.
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Blood,
December 15, 2007;
110(13):
4396 - 4405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Plonquet, C Haioun, J-P Jais, A-L Debard, G Salles, M-C Bene, P Feugier, C Rabian, O Casasnovas, M Labalette, et al.
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2 3 diffuse large B-cell lymphoma
Ann. Onc.,
July 1, 2007;
18(7):
1209 - 1215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
265 - 297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hummel, S. Bentink, H. Berger, W. Klapper, S. Wessendorf, T. F.E. Barth, H.-W. Bernd, S. B. Cogliatti, J. Dierlamm, A. C. Feller, et al.
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
N. Engl. J. Med.,
June 8, 2006;
354(23):
2419 - 2430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Reinhardt, C. Herkel, C. Altehoefer, J. Finke, and E. Moser
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Ann. Onc.,
September 1, 2005;
16(9):
1524 - 1529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, M. A. Gertz, R. A. Kyle, M. Q. Lacy, M. F. Burritt, T. M. Therneau, P. R. Greipp, T. E. Witzig, J. A. Lust, S. V. Rajkumar, et al.
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
J. Clin. Oncol.,
September 15, 2004;
22(18):
3751 - 3757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bertz, R. Zeiser, W. Lange, S. Fetscher, C. F. Waller, and J. Finke
Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index
Ann. Onc.,
September 1, 2004;
15(9):
1419 - 1424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kohlhammer, C. Schwaenen, S. Wessendorf, K. Holzmann, H. A. Kestler, D. Kienle, T. F. E. Barth, P. Moller, G. Ott, J. Kalla, et al.
Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions
Blood,
August 1, 2004;
104(3):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Zidan, O. Hussein, W. Basher, and S. Zohar
Serum CA125: A Tumor Marker for Monitoring Response to Treatment and Follow-up in Patients with Non-Hodgkin's Lymphoma
Oncologist,
July 1, 2004;
9(4):
417 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Laport, B. L. Levine, E. A. Stadtmauer, S. J. Schuster, S. M. Luger, S. Grupp, N. Bunin, F. J. Strobl, J. Cotte, Z. Zheng, et al.
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
Blood,
September 15, 2003;
102(6):
2004 - 2013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Campbell, J. P. Matthews, J. F. Seymour, M. M. Wolf, and S. K. Juneja
Optimum trephine length in the assessment of bone marrow involvement in patients with diffuse large cell lymphoma
Ann. Onc.,
February 1, 2003;
14(2):
273 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kostakoglu, M. Coleman, J. P. Leonard, I. Kuji, H. Zoe, and S. J. Goldsmith
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin's Disease
J. Nucl. Med.,
August 1, 2002;
43(8):
1018 - 1027.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Leroy, C. Haioun, E. Lepage, N. Le Metayer, F. Berger, E. Labouyrie, V. Meignin, B. Petit, C. Bastard, G. Salles, et al.
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas
Ann. Onc.,
July 1, 2002;
13(7):
1108 - 1115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Rudiger, D. D. Weisenburger, J. R. Anderson, J. O. Armitage, J. Diebold, K. A. MacLennan, B. N. Nathwani, F. Ullrich, and H. K. Muller-Hermelink
Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project
Ann. Onc.,
January 19, 2002;
13(1):
140 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Leblond, N. Dhedin, M.-F. M. Bruneel, S. Choquet, O. Hermine, R. Porcher, S. N. Quoc, F. Davi, F. Charlotte, R. Dorent, et al.
Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative Disorders
J. Clin. Oncol.,
February 1, 2001;
19(3):
772 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Front, R. Bar-Shalom, M. Mor, N. Haim, R. Epelbaum, A. Frenkel, D. Gaitini, G. M. Kolodny, and O. Israel
Aggressive Non-Hodgkin Lymphoma: Early Prediction of Outcome with 67Ga Scintigraphy1
Radiology,
January 1, 2000;
214(1):
253 - 257.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. A. Hanson, P. J. Kurtin, J. A. Katzmann, J. D. Hoyer, C.-Y. Li, J. M. Hodnefield, C. H. Meyers, T. M. Habermann, and T. E. Witzig
Immunophenotypic Analysis of Peripheral Blood and Bone Marrow in the Staging of B-Cell Malignant Lymphoma
Blood,
December 1, 1999;
94(11):
3889 - 3896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Davis, C. A. White, A. J. Grillo-Lopez, W. S. Velasquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Mohrbacher, R. Weaver, et al.
Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab
J. Clin. Oncol.,
June 1, 1999;
17(6):
1851 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grange, G. Hedelin, P. Joly, M. Beylot-Barry, M. D'Incan, M. Delaunay, L. Vaillant, M.F. Avril, J. Bosq, J. Wechsler, et al.
Prognostic Factors in Primary Cutaneous Lymphomas Other Than Mycosis Fungoides and the Sezary Syndrome
Blood,
June 1, 1999;
93(11):
3637 - 3642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini, S. Pileri, P. L. Zinzani, A. Carbone, V. Zagonel, C. Wolf-Peeters, G. Verhoef, F. Menestrina, G. Todeschini, M. Paulli, et al.
ALK+ Lymphoma: Clinico-Pathological Findings and Outcome
Blood,
April 15, 1999;
93(8):
2697 - 2706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Front, R. Bar-Shalom, M. Mor, N. Haim, R. Epelbaum, A. Frenkel, D. Gaitini, G. M. Kolodny, and O. Israel
Hodgkin Disease: Prediction of Outcome with 67Ga Scintigraphy after One Cycle of Chemotherapy
Radiology,
February 1, 1999;
210(2):
487 - 491.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J.-Y. Blay, F. Gomez, C. Sebban, T. Bachelot, P. Biron, C. Guglielmi, A. Hagenbeek, R. Somers, F. Chauvin, and T. Philip
The International Prognostic Index Correlates to Survival in Patients With Aggressive Lymphoma in Relapse: Analysis of the PARMA Trial
Blood,
November 15, 1998;
92(10):
3562 - 3568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Voorzanger-Rousselot, M.-C. Favrot, and J.-Y. Blay
Resistance to Cytotoxic Chemotherapy Induced by CD40 Ligand in Lymphoma Cells
Blood,
November 1, 1998;
92(9):
3381 - 3387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nademanee, A. Molina, M. R. O'Donnell, A. Dagis, D. S. Snyder, P. Parker, A. Stein, E. Smith, I. Planas, A. Kashyap, et al.
Results of High-Dose Therapy and Autologous Bone Marrow/Stem Cell Transplantation During Remission in Poor-Risk Intermediate- and High-Grade Lymphoma: International Index High and High-Intermediate Risk Group
Blood,
November 15, 1997;
90(10):
3844 - 3852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nagler, A. Ackerstein, R. Or, E. Naparstek, and S. Slavin
Immunotherapy With Recombinant Human Interleukin-2 and Recombinant Interferon-alpha in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation
Blood,
June 1, 1997;
89(11):
3951 - 3959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Engelhard, G. Brittinger, D. Huhn, H. H. Gerhartz, P. Meusers, W. Siegert, E. Thiel, W. Wilmanns, U. Aydemir, S. Bierwolf, et al.
Subclassification of Diffuse Large B-Cell Lymphomas According to the Kiel Classification: Distinction of Centroblastic and Immunoblastic Lymphomas Is a Significant Prognostic Risk Factor
Blood,
April 1, 1997;
89(7):
2291 - 2297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsunoda, S. Takagi, O. Tanaka, and Y. Miura
Clinical and Prognostic Significance of Femoral Marrow Magnetic Resonance Imaging in Patients With Malignant Lymphoma
Blood,
January 1, 1997;
89(1):
286 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Philip, C. Guglielmi, A. Hagenbeek, R. Somers, H. Van Der Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J.-Y. Cahn, J.-L. Harousseau, et al.
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
N. Engl. J. Med.,
December 7, 1995;
333(23):
1540 - 1545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
